SPOTLIGHT: Baxter touts Alzheimer's data
Baxter International's Gammagard intravenous plasma-based treatment demonstrated an ability to improve the mental functions of patients with mild moderate Alzheimer's in a small trial. The trial hit its primary goals in a six-month study involving 24 patients. Secondary endpoints relating to beta-amyloid and anti- amyloid antibody levels were also hit. Recruitment for Phase III begins later in the year. Release
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
